Conference Proceedings

A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine.

Macarena Ines De La Fuente, Howard Colman, Mark Rosenthal, Brian Andrew Van Tine, Danijela Levaci, Tobias Walbert, Hui Kong Gan, Maria Vieito, Mohammed M Milhem, Kate Lipford, Sanjeev Forsyth, Sylvie Mireille Guichard, Yelena Mikhailov, Alexander Sedkov, Blythe Thomson, Patrick Francis Kelly, Varun Monga

JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020

University of Melbourne Researchers

Grants

Funding Acknowledgements

FORMA Therapeutics, Inc.